Vigabatrin For Solution
Product Images NDC 72205-093

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Vigabatrin (NDC 72205-093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vigabatrin-500mg-carton-label (Vigabatrin 500mg Carton Label)

The packaging label for Vigabatrin for Oral Solution, USP 500 mg by Novadoz Pharmaceuticals LLC shows a box containing 50 packets. It includes dosing instructions to mix each packet with 10 mL of water before administration. The label also states storage conditions, the manufacturer (MSN Laboratories, India), and distributor details. This is a prescription drug for oral use.*

FDA Label Image

Vigabatrin-500mg-packet-label (Vigabatrin 500mg Packet Label)

Vigabatrin for Oral Solution, USP 500 mg packet packaging label. It is marked Rx only and includes instructions for pharmacists to dispense the Medication Guide. The label shows the Novadoz Pharmaceuticals LLC logo and contact information. The product NDC is 72205-093-61, and the package contains 1 packet of oral solution.*

FDA Label Image

Vigabatrin-figure-1 (Vigabatrin Figure 1)

A line graph depicting the percentage reduction in seizure frequency versus the percentage of patients for different treatment groups. The graph compares placebo and three dosages of Vigabatrin (1g/day, 3g/day, and 6g/day), showing trends in seizure frequency improvement and worsening across patient percentages.*

FDA Label Image

Vigabatrin-figure-2 (Vigabatrin Figure 2)

A figure showing a cumulative percentage plot comparing the percentage reduction in seizure frequency versus the percent of patients for two groups: placebo and 3g/day Vigabatrin (VGB). The vertical axis shows percentage reduction in seizures ranging from -100% (worsening) to 100% (improvement), with a horizontal line at zero indicating no change. The horizontal axis shows percent of patients from 100% to 0%. Two lines represent patient response distributions for placebo and 3g/day VGB treatment.*

FDA Label Image

Vigabatrin-figure-3 (Vigabatrin Figure 3)

The image shows a medication packet labeled Vigabatrin for Oral Solution, USP, 500 mg, alongside a glass of water, a spoon, and two syringes, suggesting preparation for oral dosing. The packet is from the labeler MBNO and is intended for single use.*

FDA Label Image

Vigabatrin-figure-4 (Vigabatrin Figure 4)

An illustration showing details of an oral syringe used for medication administration. The parts labeled include the tip, dosage indicators, barrel, bottom of the white plunger, and the plunger itself.*

FDA Label Image

Vigabatrin-figure-a (Vigabatrin Figure A)

An instructional illustration labeled "Figure A" showing a packet of Vigabatrin Oral Solution USP 500 mg being poured into a clear glass. The image demonstrates the preparation or administration step for the oral solution dosage form.*

FDA Label Image

Vigabatrin-figure-b (Vigabatrin Figure B)

Illustration showing two clear glass containers side by side on a gray surface. The left container holds a transparent liquid to about one-third of its height, while the right container is empty. The image is labeled as Figure B.*

FDA Label Image

Vigabatrin-figure-c (Vigabatrin Figure C)

An illustration labeled 'Figure C' showing a hand holding a syringe that is being submerged in a transparent glass of water, likely demonstrating how to mix or prepare the oral solution of Vigabatrin 50 mg/mL.*

FDA Label Image

Vigabatrin-figure-d (Vigabatrin Figure D)

Illustration showing a hand holding an oral syringe filled with liquid medication, demonstrating usage technique for administering the drug via oral route.*

FDA Label Image

Vigabatrin-figure-e (Vigabatrin Figure E)

An instructional illustration showing a hand holding a calibrated oral syringe filled to the 10 mL line, as indicated by an arrow and label. The image is likely related to measuring the oral solution dosage of Vigabatrin.*

FDA Label Image

Vigabatrin-figure-f (Vigabatrin Figure F)

An instructional illustration showing a hand holding an oral syringe dispensing liquid into a glass cup. The image likely demonstrates the method of measuring or administering a liquid oral dosage form such as Vigabatrin 50 mg/mL oral solution.*

FDA Label Image

Vigabatrin-figure-g (Vigabatrin Figure G)

Black and white instructional image showing a hand holding a spoon inside a clear glass container, labeled as Figure G. The image appears to demonstrate a step related to preparing or administering an oral solution, possibly for Vigabatrin 50 mg/mL.*

FDA Label Image

Vigabatrin-figure-h (Vigabatrin Figure H)

Illustration labeled 'Figure H' showing a hand holding a syringe being rinsed or inserted into a small glass container. The syringe has measurement markings visible, suggesting a step in medication preparation or administration.*

FDA Label Image

Vigabatrin-figure-i (Vigabatrin Figure I)

Illustration labeled as Figure I showing a close-up of a hand holding a syringe with measurement markings, likely demonstrating preparation or dosing technique for an oral solution drug product.*

FDA Label Image

Vigabatrin-figure-j (Vigabatrin Figure J)

An instructional illustration labeled Figure J showing a hand administering oral medication to a small child using a syringe-like device inserted into the child's mouth.*

FDA Label Image

Vigabatrin-structure (Vigabatrin Structure)

Chemical structure of vigabatrin, showing its molecular framework including an amino group, a vinyl group, and a carboxylic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.